Thermostabilization of proteins
Provided are compositions comprising a cocaine esterase (CocE) and a compound that thermostabilizes the CocE. Also provided are methods of thermostabilizing a cocaine esterase. Additionally provided are methods of treating a mammal undergoing a cocaine-induced condition. Methods of determining whether a compound is a thermostabilizing agent for a protein are also provided. Uses of the above-described compositions for the treatment of a cocaine-induced condition is additionally provided. Additionally provided is an isolated nucleic acid encoding a CocE polypeptide having the substitutions L169K and G173Q, and the CocE polypeptide encoded by that nucleic acid, and pharmaceutical compositions thereof. Further provided is the use of that composition for the manufacture of a medicament for the treatment of a cocaine-induced condition and for the treatment of a cocaine-induced condition.
1. A method of treating a cocaine-induced condition, the method comprising:
administering to a mammalian subject in need thereof an effective amount of a composition comprising
a cocaine esterase (CocE) polypeptide comprising an amino acid sequence at least 85% identical to SEQ ID NO: 1 having esterase activity; and
at least one thermostabilization compound selected from
wherein,
the CocE in the presence of the compound is more thermostable than the CocE in the absence of the compound and
the subject is diagnosed with, or at risk for, a cocaine-induced condition selected from the group consisting of cocaine overdose, cocaine toxicity, cocaine addiction, or cocaine dependence.
2. The method of claim 1 , wherein the CocE polypeptide comprises
an amino acid sequence at least 90% identical to SEQ ID NO: 1 having esterase activity; or
an amino acid sequence at least 90% identical to SEQ ID NO: 1 with one or more substitutions selected from the group consisting of L163V, V225I, I218L, A310D, A149S, S159A, S265A, S56G, W220A, S140A, F189L, A193D, T254R, N42V, V262L, L508G, Y152H, V160A, T172R, Y532F, T74S, W285T, L146P, D533S, A194R, G173Q, C477T, K531A, R41I, L119A, K46A, F84Y, T172R/G173Q, L169K, F189A, N197K, R182K, F189K, V190K, Q191K, A194K, and L169K/G173Q, or a combination thereof; and having esterase activity.
3. The method of claim 1 , wherein the composition is administered by intravenous, intramuscular, subcutaneous, or intraperitoneal injection.
4. The method of claim 2 , wherein the at least one thermostabilization compound is selected from:
5. The method of claim 1 , wherein the at least one thermostabilization compound is selected from:
6. The method of claim 1 , wherein the at least one thermostabilization compound is:
7. The method of claim 1 , wherein the CocE polypeptide cocaine esterase comprises an amino acid sequence at least 90% identical to SEQ ID NO: 1 with one or more substitutions selected from the group consisting of L163V, V225I, I218L, A310D, A149S, S159A, S265A, S56G, W220A, S140A, F189L, A193D, T254R, N42V, V262L, L508G, Y152H, V160A, T172R, Y532F, T74S, W285T, L146P, D533S, A194R, G173Q, C477T, K531A, R41I, L119A, K46A, F84Y, T172R/G173Q, L169K, F189A, N197K, R182K, F189K, V190K, Q191K, A194K, and L169K/G173Q, or a combination thereof; and having esterase activity.
8. The method of claim 1 , wherein the CocE polypeptide cocaine esterase comprises an amino acid sequence of SEQ ID NO: 1 with one or more substitutions selected from the group consisting of: T172R, S159A, N197K, L169K, F189K, G173Q, and T172R/G173Q.
9. The method of claim 1 , wherein the CocE polypeptide comprises an amino acid sequence having at least 85% sequence identity with SEQ ID NO:1, having substitutions L169K/G173Q, esterase activity, and increased thermostability at 37 ° C. as compared to wild-type CocE.
10. The method of claim 1 , wherein the CocE polypeptide comprises an amino acid sequence of SEQ ID NO:1 with substitutions L169K/G173Q.
11. The method of claim 1 , wherein the CocE polypeptide cocaine esterase comprises an amino acid sequence of SEQ ID NO: 1.
12. The method of claim 1 , wherein the CocE polypeptide is a pegylated CocE polypeptide.
13. The method of claim 1 , wherein the composition comprises a pharmaceutically acceptable carrier.
14. The method of claim 1 , wherein the composition is administered by intravenous injection.
15. The method of claim 1 , wherein the composition is administered via a mini-infusion pump.
16. The method of claim 1 , wherein the mammalian subject is selected from the group consisting of a rodent, rabbit, guinea pig, horse, cow, dog, cat, sheep, pig, and human.
17. The method of claim 1 , wherein the mammalian subject is a human.